Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
China Mobile Returns to A-share Market Planning to Issue 965 Mn Shares
The announcement shows that the funds raised by the telecommunication company will be used for projects such as 5G boutique network construction, new Cloud infrastructure construction, gigabit smart home construction, new-generation information technology research and development, digital intelligence ecology construction, and so on.
May 18, 2021 11:28 AM
EqualOcean | Southern Weekly 2022 'China Greenwashing List'
Oct 03, 2023 12:37 PM
2022 ESG Report Analysis | Yili: The Practical Path of ESG
Sep 28, 2023 09:01 PM
An Analysis of Domestic ESG Rating Agencies in China
Sep 28, 2023 12:46 PM